Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00529360 · ClinicalTrials.gov registry record · Phase 1
Allogeneic Stem Cell Transplant With Clofarabine, Ara-C and TBI for AML and ALL
A Phase 1 study, sponsored by New York Medical College.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT00529360 is a Phase 1 study that has completed, run by New York Medical College. The registered enrollment target is 32 participants.
The verdict
NCT00529360, a Phase 1 study, has completed, sponsored by New York Medical College.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
Hypothesis: Myeloablative conditioning using a dose escalation of clofarabine in combination with cytarabine (ARA-C) and total body irradiation (TBI) will lead to improved survival for previously untransplanted children and adolescents with acute lymphoblastic leukemia (ALL) and acute non-lymphoblastic leukemia (ANLL)followed by allogeneic stem cell transplantation (AlloSCT).
Interventions
- DRUG Clofarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2007-06 |
| Est. Completion | 2016-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00529360
The ClinicalTrials.gov registry entry for NCT00529360 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York Medical College, which has 47 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Clofarabine is the first listed.
NCT00529360 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00529360 about?
NCT00529360 is a clinical study titled "Allogeneic Stem Cell Transplant With Clofarabine, Ara-C and TBI for AML and ALL". Hypothesis: Myeloablative conditioning using a dose escalation of clofarabine in combination with cytarabine (ARA-C) and total body irradiation (TBI) will lead to improved survival for previously untransplanted children and adolescents with acute lymphoblastic leukemia (ALL) and acute non-lymphoblas...
What is the current status of trial NCT00529360?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2007-06. Estimated completion is 2016-03.
What interventions are being tested in trial NCT00529360?
The interventions under investigation include: Clofarabine (DRUG).
Who is sponsoring clinical trial NCT00529360?
This trial is sponsored by New York Medical College, which has 47 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.